AKESO(09926) 交银国际证券·2024-10-03 15:07Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 87.00, indicating a potential upside of 25.8% from the current price of HKD 69.15 [2][7]. Core Insights - The report highlights the approval of two new indications for the company's products, significantly expanding its commercial portfolio into non-oncology areas. The approval of the drug 开坦尼 for first-line treatment of gastric cancer is expected to greatly increase its potential patient population, with an estimated peak sales forecast adjustment to RMB 5.2 billion. Additionally, the approval of AK102 for primary hypercholesterolemia and mixed dyslipidemia is noted as a strong competitive advantage in the market [1][2]. - Recent clinical data releases from major conferences such as ESMO and EADV have shown promising results for the company's products, particularly for IL-17 古莫奇单抗 in treating moderate to severe plaque psoriasis and for the drug 依沃西 in various solid tumors, which may enhance the clinical application and extend the product lifecycle [1][2]. Financial Summary - Revenue projections for 2024-2026 have been increased by 6-10% due to the recent approvals and positive clinical developments. The new revenue estimates are RMB 2,849 million for 2024, RMB 4,786 million for 2025, and RMB 6,465 million for 2026, reflecting significant growth compared to previous forecasts [4][5]. - The company is expected to report a net profit of RMB 786 million in 2025 and RMB 1,880 million in 2026, indicating a recovery from losses in 2024 [4][5]. - The DCF valuation model suggests a fair value of HKD 87.0 per share, supported by anticipated catalysts such as the outcomes of insurance negotiations and the approval of new indications [2][6].